Portable tumor biosensing of serum by plasmonic biochips in combination with nanoimprint and microfluidics

Nanophotonics

article

Jianyang Zhou¹  Qing Huo Liu²  Feng Tao¹  Jinfeng Zhu¹  Shaowei Lin³  Zhengying Wang¹  Xiang Wang⁴  Jun-Yu Ou⁵  Yuan Li⁶ 

[1] School of Electronic Science and Engineering, Xiamen University;Department of Electrical and Computer Engineering, Duke University;The First Affiliated Hospital of Xiamen University;State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, Xiamen University;Optoelectronics Research Centre and Centre for Photonic Metamaterials, University of Southampton;Central Laboratory of Yongchuan Hospital, Chongqing Medical University

关键词: plasmonics;    nanoimprint lithography;    biosensing;    microfluidics;    immunochip;   

DOI  :  10.1515/nanoph-2018-0173

学科分类：社会科学、人文和艺术（综合）

来源: De Gruyter

【 摘 要 】

Plasmonic sensing has a great potential in the portable detection of human tumor markers, among which the carcinoembryonic antigen (CEA) is one of the most widely used in clinical medicine. Traditional plasmonic and non-plasmonic methods for CEA biosensing are still not suitable for the fast developing era of Internet of things. In this study, we build up a cost-effective plasmonic immunochip platform for rapid portable detection of CEA by combining soft nanoimprint lithography, microfluidics, antibody functionalization, and mobile fiber spectrometry. The plasmonic gold nanocave array enables stable surface functionality, high sensitivity, and simple reflective measuring configuration in the visible range. The rapid quantitative CEA sensing is implemented by a label-free scheme, and the detection capability for the concentration of less than 5 ng/ml is achieved in clinical experiments, which is much lower than the CEA cancer diagnosis threshold of 20 ng/ml and absolutely sufficient for medical applications. Clinical tests of the chip on detecting human serums demonstrate good agreement with conventional medical examinations and great advantages on simultaneous multichannel detections for high-throughput and multi-marker biosensing. Our platform provides promising opportunities on low-cost and compact medical devices and systems with rapid and sensitive tumor detection for point-of-care diagnosis and mobile healthcare.

【 授权许可】

CC BY